Alibaba Health and Hansoh Pharma Sign Strategic Cooperation Agreement to Explore Digital Smoking Cessation Solutions

Aug 05, 2025 11:49 CST Updated 11:49

AliHealth

Medical and Health Services Network Service Provider

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

On July 30, AliHealth and Hansoh Pharma signed a strategic cooperation agreement in Hangzhou. As the first phase of the cooperation pilot,The two parties will deepen cooperation around the development of Hansoh Pharma's Aimitinovir Tablets and its central nervous system pipeline, as well as the digital marketing of the smoking cessation drug Varenicline Tartrate Tablets.

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases. To date, the company has launched 7 innovative drugs, forming a rich product pipeline.

Published by the National Health CommissionResults from the 2024 China Adult Tobacco Survey show that the smoking rate among people aged 15 and above in China is 23.2%.Medication intervention is one of the effective ways to quit smoking.Hansoh Pharma's Smoking Cessation DrugVarenicline Tartrate TabletsThrough a unique dual-effect mechanism, it can both alleviate withdrawal discomfort symptoms and block the pleasure of smoking.【1】

Hansoh PharmaWill join hands withAliHealth jointly explores new paths for digital smoking cessation. From the initial assessment of the willingness to quit smoking, to online consultations with professional physicians during medication, and then to follow-up tracking to prevent relapse after quitting.。In the future, the cooperation between the two parties will expand to a broader range of product areas, allowing more innovative drugs to quickly and accurately benefit patients.

References:

【1】Jorenby DE et al. JAMA. 2006;296:56-63.; Gonzales D et al. JAMA. 2006;296:47-55.